HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

RBC Capital raises Neurocrine Biosciences price target

Created at 4 Jun · 8:29 AM4 sources↑ Market-relevant4 events
IN SHORT

RBC Capital has increased its price target on Neurocrine Biosciences (NBIX), citing a revised outlook on the company's stock performance.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Who's Involved

RBC Capital
Analyst firm raising Neurocrine Biosciences price target
Neurocrine Biosciences
Company whose stock price target was raised

↳ Why This Matters

Analyst price target changes can influence investor sentiment and stock valuation.

Key facts

  • RBC Capital raised its price target on Neurocrine Biosciences.
  • The adjustment reflects a revised outlook on the company's stock performance.

RBC Capital has raised its price target on Neurocrine Biosciences (NBIX). This adjustment reflects a revised outlook on the company's stock performance.

Frequently asked questions

Neurocrine Biosciences (NBIX) had its price target raised.

RBC Capital raised the price target.

The adjustment reflects a revised outlook on the company's stock performance.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

4 Jun · 8:48 PM
RBC Capital raised Oracle's stock price target to $190, a change unrelated to ADC Therapeutics.
Investing.com via PiQSuite
4 Jun · 4:49 PM
RBC Capital raises price target on Neurocrine Biosciences (NBIX), reflecting a revised outlook.
Yahoo News | Finance Top Stories via PiQSuite
4 Jun · 11:02 AM
ADC Therapeutics' confirmatory trial for lymphoma therapy failed to meet its primary endpoint, causing its stock to fall.
Seeking Alpha via PiQSuite
4 Jun · 8:01 AM
RBC Capital lowered its rating on ADC Therapeutics stock following trial results, though specific outcomes were not detailed.
Investing.com via PiQSuite

Sources

T1
RBC Capital cuts ADC Therapeutics stock rating on trial resultsm.piqsuite.com
T1
ADC Therapeutics falls on confirmatory trial data for lymphoma therapym.piqsuite.com
T1
RBC Capital raises Oracle stock price target to $190 on peer multiplesm.piqsuite.com
T1
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)m.piqsuite.com

Related Stories

Memory Stocks Plunge as Year's Hottest Trade Unravels
8 Jul · 2:35 PM
JPMorgan Hires Michael Flynn to Lead New Small-Cap Banking Business
8 Jul · 3:03 PM
SpaceX Analyst Maintains Neutral Stance Amid Wall Street Buy Frenzy
8 Jul · 10:00 AM
Honeywell Technologies raises 2026 profit targets after reverse stock split
8 Jul · 9:08 PM
HSBC downgrades EM equities on AI spending fears
8 Jul · 12:04 PM